U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the deal two years ...

EU regulators have approved Illumina's (ILMN) plans to divest Grail, the cancer test developer it acquired, despite antitrust concerns. Read more here.

Nvidia’s takeover of Israeli streamlining provider Run:ai cleared a key regulatory hurdle with EU approval without conditions.

The European Union has approved a 150 billion-euro plan to significantly boost defense spending within the bloc through joint procurements and market loans, aimed at enhancing security and ...

EU antitrust regulators plan to order U.S. life sciences firm Illumina to divest biotechnology company Grail after an EU veto of the $7.1 billion acquisition over concerns it would hurt ...

The European Union on Thursday ordered US biotech giant Illumina to undo its $7.1 billion purchase of cancer-screening company Grail because it closed the deal without approval of regulators in ...

U.S. biotech firm Illumina was hit with a record antitrust fine of $476 million (€432 million) by the European Union Wednesday for failing to secure regulatory approval from the bloc for its $7. ...

The European Commission fined biotech firm Illumina 432 million euros ($476 million) for closing its acquisition of Grail without the commission's approval, in the Commission's largest merger ...

But Illumina still must submit a plan to the commission for approval. In the meantime, the companies must remain separate and the commission has directed Illumina to fund Grail’s cash needs to ...

Chinese-founded fast-fashion company Shein will have to comply with tough new EU online content rules after its user numbers soared above a key benchmark, joining a score of other Big Tech ...

BRUSSELS (Reuters) -U.S. gene sequencing company Illumina's plan to divest cancer diagnostic test maker Grail received the green light from EU antitrust regulators on Friday after having blocked the ...